Daily India: Metropolis Healthcare IPO: Stands Apart in Pricing Power, Revenue Growth and Margins and more

In this briefing:

1. Metropolis Healthcare IPO: Stands Apart in Pricing Power, Revenue Growth and Margins
2. Shaily Engineering-Q2FY18 Results Update
3. Godrej Agrovet to Merge with Astec Lifesciences: An Arbitrage Opportunity Coupled with Concerns.
4. CCL Products Q2 FY19 Results Update- Moving up the Value Chain as Expected
5. Bleak Future for Indusind Bank

1. Metropolis Healthcare IPO: Stands Apart in Pricing Power, Revenue Growth and Margins

• Metropolis Health Services Limited (MHL IN) is the 3^rd largest pathology chain in India and caters to the Rs600bn market growing at 15% Cagr. It is strongest in the lucrative Mumbai and Chennai markets.
• Though India’s pathology market has seen intense price competition and price discounting, Metropolis managed to grow revenue/patient much ahead of peers
• Its revenue/patient is 20% higher than its nearest competitor and the gap has been widening over FY16-18
• It is the only major pathology chain to have accelerated revenue growth over FY16-18 despite the lowest A&P spend
• It managed to grow Gross Margin 330bps and hold Ebitda margins over FY16-18. Major competitors like Dr Lal Pathlabs (DLPL IN) (-340bps) and SRL (-520bps) saw sharp contraction in Ebitda margins.
• On the flip side, its patient growth has lagged its retail network growth by a wide margin. Its cash conversion cycle is much longer than DLAL’s. It is also the most vulnerable to any government regulated price caps on testing in the future owing to its premium pricing.
• Lastly, it doesn’t need any fresh money and the entire IPO is an offer for sale by the promoters and Carlyle Group.

2. Shaily Engineering-Q2FY18 Results Update

Shaily Engineering Plastics (SHEP IN) Q2 FY19 results were below our expectations. While revenue increased by 10% YoY, PAT declined by 9% YoY in Q2 FY19. This muted performance was primarily due higher raw material prices and a shortage of labour as well as power outage that resulted in low machine utilization. We analyze the results.

3. Godrej Agrovet to Merge with Astec Lifesciences: An Arbitrage Opportunity Coupled with Concerns.

Godrej Agrovet is a large conglomerate operating in various business verticals in the agriculture sector. It is looking to merge with Astec LifeSciences which is a pure agro-chemical company that focusses on Chemical molecule production and formulation for domestic and export markets. In this report, we analyze the implications of the merger as well as the impact on minority shareholders in both companies.

4. CCL Products Q2 FY19 Results Update- Moving up the Value Chain as Expected

Ccl Products India (CCLP IN) Q2 FY19 results were beyond our expectations. Although the revenues declined by 2% YoY in Q2 FY19 due to lower realization as the green coffee prices have declined by near 20% YoY in Q2 FY19, PAT increased by 41% YoY (against our expectation of 20% YoY growth) due to higher capacity utilization and improving share of value added products in the revenue mix.

We analyze the results.

5. Bleak Future for Indusind Bank

Indusind Bank’s reckless decision to provide a Rs 20 bn (8% of the bank’s capital) unsecured bridge loan to IL&FS, an insolvent infrastructure company has led to a significant de-rating of its valuation multiple. In the 3QFY2019 results call, Ramesh Sobti, the bank’s CEO believes that the bank will eventually need to provide only 40-50% of this exposure and the bank has currently provided only 26.5%. The bank’s guidance on this appears to be as optimistic as its initial appraisal when it disbursed the loan, without any apparent scrutiny of the company’s financials. Shareholders in the bank need to be more realistic and factor a 100% write-off on the unsecured IL&FS exposure and need to examine all the bank’s loans more carefully for similar high-risk lending. The glory days of this once fancied stock are over and a bleak future beckons.